AngioDynamics, Inc. (ANGO) – What Are Researchers Saying About This Stock?

AngioDynamics, Inc. (NASDAQ:ANGO) has received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $19.00.

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of AngioDynamics in a research report on Friday, October 9th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. HC Wainwright dropped their price objective on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Thursday, October 15th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CFO Stephen Trowbridge sold 23,615 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $12.27, for a total value of $289,756.05. Following the completion of the transaction, the chief financial officer directly owned 280,461 shares in the company, valued at approximately $3,441,256.47. This represents a 7.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of AngioDynamics in the second quarter valued at approximately $49,480,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics during the 2nd quarter worth about $17,649,392. Bastion Asset Management Inc. raised its holdings in AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after acquiring an additional 194,822 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of AngioDynamics by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after acquiring an additional 32,476 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in AngioDynamics by 0.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock valued at $8,624,000 after acquiring an additional 5,509 shares during the period. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $11.73 on Monday. The firm has a market cap of $493.25 million, a P/E ratio of -15.04 and a beta of 0.30. The firm’s fifty day moving average is $13.79 and its 200-day moving average is $12.50. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The business had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.